Long-term Benefit of MPA in Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-04

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation

NCT00007059

Graft Versus Host Disease

COMPLETED NA

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

NCT00658333

Renal Transplantation

TERMINATED PHASE4

Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients

NCT00780429

Kidney Transplantation

UNKNOWN

Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients

NCT00149903

Renal Transplant

COMPLETED PHASE3

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076

Liver Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Rejection Immunosuppressant Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MPA

Immunosuppressant with enteric-coated mycophenolate sodium

enteric-coated mycophenolate (MPAs)

Intervention Type DRUG

Immunosuppression protocol with enteric-coated mycophenolate sodium

None MPA

Immunosuppressant without enteric-coated mycophenolate sodium

None MPA

Intervention Type DRUG

Immunosuppression protocol without enteric-coated mycophenolate sodium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

enteric-coated mycophenolate (MPAs)

Immunosuppression protocol with enteric-coated mycophenolate sodium

Intervention Type DRUG

None MPA

Immunosuppression protocol without enteric-coated mycophenolate sodium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who underwent their first liver transplantation between January 1, 2016 and February 28, 2021;
* Recipient's survival time≥ 1 year;
* Age 18\~65 years old;
* Patients with complete data and no loss to follow-up.

Exclusion Criteria

* use of other types of anti-metabolic immunosuppressants;
* Second liver transplantation for various reasons within 1 year after the first transplantation;
* Patients with serious underlying diseases, including heart disease, infection and renal insufficiency, combined with other malignant tumors.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No